UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) November 6, 2002
------------------------------
TRIANGLE PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 000-21589 56-1930728
---------------------------- ---------------------- ----------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
4 University Place, 4611 University Drive, Durham, North Carolina 27707
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (919) 493-5980
--------------------------
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS
On November 6, 2002, Triangle Pharmaceuticals, Inc. issued a press release,
a copy of which is attached hereto as Exhibit 99.1, and is incorporated herein
by reference.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits. The following document is incorporated by reference
to this Report:
99.1 Press release dated November 6, 2002.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Triangle Pharmaceuticals, Inc.
--------------------------------
(Registrant)
November 7, 2002 /s/ Daniel G. Welch
----------------------------------------- --------------------------------
Date (Signature)
Name: Daniel G. Welch
Title: Chairman & Chief
Executive Officer